Travel grant 2024 Switzerland, Swiss Nordic Bio 2024 on March 7

Purpose and goal:

Amferia is in a scale-up phase with rapidly growing customer base in Animal wound care and awaiting regulatory clearance in the US for human wound care applications. In this regard, we met with investors and partners for supporting the scale-up at the SwissNordicBio through 1-1 meetings and 5 minute presentations.

Expected results and effects:

The main result is new investor contacts who may be interested for supporting our Series A investment round. Additionally, we also met with possible commercial contacts for distribution. Approach and implementation:

The event enabled Amferia to present the company for 5 minutes in front of a broad audience, followed by focussed 1-1 meetings. The implementation of the event supported the accomplishment of the expected result.